Company Announcements

Bigfoot Biomedical Announces Insulin Compatibility Expansion to Support Insulin Affordability and Flexibility for People with Diabetes

MILPITAS, Calif.--(BUSINESS WIRE)--Nov. 7, 2022-- Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, today announced its Bigfoot Unity® Diabetes Management System is now compatible with four additional rapid-acting insulin products, including two unbranded biologics. All four insulin products are offered at a reduced price without compromising quality, helping to expand insulin access for people with diabetes.1

“Bigfoot recognizes the urgent need to provide millions of Americans with affordable access to diabetes care. It is a critical part of our mission,” said Jeffrey Brewer, CEO of Bigfoot Biomedical. “Our expansion of compatibility to include additional insulin brands will make it easier for Bigfoot to support a broader population of people with insulin-requiring diabetes and will give Bigfoot Unity users greater flexibility to switch between insulin brands when they have a change in insurance. This news marks an important moment in time for Bigfoot as we strive to make insulin diabetes management tools more accessible for people who need them.”

The Bigfoot Unity System, the first and only FDA-cleared dose decision support system based on CGM data for people using multiple daily injections, features smart pen caps compatible with a broad range of disposable insulin pens for both long-acting and rapid-acting insulin. Effective immediately, the system will also be compatible with the following:

  • Eli Lilly’s (LLY: NYSE) Insulin Lispro, an unbranded biologic that is the same molecule as Humalog®
  • Novo Nordisk’s (NVO:NYSE) Insulin Aspart, an unbranded biologic that is the same molecule as Novolog®
  • ReliON NovoLog® insulin, a private brand analog insulin manufactured by Novo Nordisk and available exclusively at Walmart and Sam’s Club pharmacies; ReliOn is the same molecule as Novolog

The above insulins are available at a list price at least 50% lower than their branded equivalent.2

The Bigfoot Unity system is also now compatible with Eli Lilly’s Lyumjev® (insulin lispro-aabc injection), a new rapid-acting insulin from Lilly that is included in the Lilly Insulin Value Program, allowing anyone with commercial insurance and those without insurance to fill their monthly prescription of Lyumjev for $35.

The decision to offer lower-priced insulin products as a compatible option with the Bigfoot Unity system is just one step the company is taking to expand access for people with insulin-requiring diabetes. The company is also taking action to make its insulin management technology more broadly available to people in rural communities and is working to improve access for Medicare and Medicaid populations.

About Bigfoot Biomedical, Inc.

Bigfoot Biomedical was founded by a team of people with personal connections to Type 1 and Type 2 diabetes. We seek to change the paradigm of care for diabetes. Bigfoot is an unconventional company taking an unconventional approach. Unlike others, we look at insulin therapy holistically, and utilize services, support, and novel business models. We’re partnering with healthcare professionals to deliver simple, connected, and comprehensive solutions for the large number of people who have been overlooked by diabetes innovation. Learn more on our website and by following us on LinkedIn, Twitter, Instagram, and Facebook.

1 Insulin is now a biologic-what does that mean?, American Diabetes Association, https://diabetes.org/blog/insulin-now-biologic-what-does-mean
2 Data on file with Bigfoot Biomedical

All product and company names are trademarksor registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

Jessica Stebing
T +1 260 336 6202
jstebing@healthandcommerce.com

Source: Bigfoot Biomedical, Inc.